Race against mpox: Unicef secures emergency vaccine supply, ready to roll out millions of doses to crisis-hit areas

Race against mpox: Unicef secures emergency vaccine supply, ready to roll out millions of doses to crisis-hit areas
Race against mpox: Unicef secures emergency vaccine supply, ready to roll out millions of doses to crisis-hit areas

Hello and welcome to the details of Race against mpox: Unicef secures emergency vaccine supply, ready to roll out millions of doses to crisis-hit areas and now with the details

Nevin Al Sukari - Sana'a - The United Nations Children’s Fund (Unicef) has issued an emergency tender to secure mpox vaccines for crisis-hit countries in collaboration with the Gavi vaccine alliance, Africa CDC and the World Health Organization, the organizations said in a joint statement on Saturday. — Reuters pic

NEW YORK, Sept 1 — The United Nations Children’s Fund (Unicef) has issued an emergency tender to secure mpox vaccines for crisis-hit countries in collaboration with the Gavi vaccine alliance, Africa CDC and the World Health Organization, the organizations said in a joint statement yesterday.

Depending on the production capacity of manufacturers, agreements for up to 12 million doses through 2025 can be made, according to the statement.

Under the tender, Unicef will set up conditional supply agreements with vaccine manufacturers, the statement said.

This will enable Unicef to purchase and ship vaccines without delay, once financing, demand, readiness and regulatory requirements are confirmed.

The collaboration — which would also include working with the Vaccine Alliance and the Pan American Health Organization as well as with Gavi, the Africa Centers for Disease Control and Prevention and WHO — would facilitate donations of vaccines from existing stockpiles in high-income countries.

The statement added that WHO is reviewing information submitted by manufacturers on August 23, and expects to complete a review for an emergency use listing by mid-September.

The agency is reviewing applications for emergency licences for two vaccines made by Bavarian Nordic and Japan’s KM Biologics.

Earlier in August, the WHO declared mpox a global public health emergency following an outbreak of the viral infection in the Democratic Republic of Congo that spread to neighbouring countries.

More than 18,000 suspected cases of mpox have been reported in Congo so far this year with 629 deaths, while over 150 cases have been confirmed in Burundi, WHO Director-General Tedros Adhanom Ghebreyesus said.

Sweden and Thailand have confirmed cases of the clade Ib type of the virus, outside of the Democratic Republic of Congo and neighbouring countries. — Reuters

These were the details of the news Race against mpox: Unicef secures emergency vaccine supply, ready to roll out millions of doses to crisis-hit areas for this day. We hope that we have succeeded by giving you the full details and information. To follow all our news, you can subscribe to the alerts system or to one of our different systems to provide you with all that is new.

It is also worth noting that the original news has been published and is available at Malay Mail and the editorial team at AlKhaleej Today has confirmed it and it has been modified, and it may have been completely transferred or quoted from it and you can read and follow this news from its main source.

PREV Japan slams China for back-to-back territorial violations
NEXT Elon Musk vs. Brazilian supreme court: What’s behind the X shutdown order?

Author Information

I am Joshua Kelly and I focus on breaking news stories and ensuring we (“Al-KhaleejToday.NET”) offer timely reporting on some of the most recent stories released through market wires about “Services” sector. I have formerly spent over 3 years as a trader in U.S. Stock Market and is now semi-stepped down. I work on a full time basis for Al-KhaleejToday.NET specializing in quicker moving active shares with a short term view on investment opportunities and trends. Address: 838 Emily Drive Hampton, SC 29924, USA Phone: (+1) 803-887-5567 Email: [email protected]